Evidence map›Paper›PMID 22125448›Full record

ReviewTheScientificWorldJournal2011

Regulation of neutrophil survival/apoptosis by Mcl-1.

Eric Milot, János G Filep

Abstract readReview
In one paragraph

Review in TheScientificWorldJournal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed.

  1. Article
  2. Article
  3. The hypoxic microenvironment ofFrontiers in immunology · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Frontiers in pharmacology · 2019
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Harnessing Neutrophil Survival Mechanisms during Chronic Infection byFrontiers in cellular and infection microbiology · 2017
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Eric MilotDepartment of Medicine, Research Center Maisonneuve-Rosemont Hospital, University of Montreal, 5415 Boulevard de l'Assomption, Montreal, QC, Canada H1T 2M4.
János G Filep

Funding

Canadian Institutes of Health Research MOP-67054Canadian Institutes of Health Research MOP-97742
6 · The paper itself

Abstract

Neutrophil granulocytes have the shortest lifespan among leukocytes in the circulation and die via apoptosis. At sites of infection or tissue injury, prolongation of neutrophil lifespan is critical for effective host defense. Apoptosis of inflammatory neutrophils and their clearance are critical control points for termination of the inflammatory response. Evasion of neutrophil apoptosis aggravates local injury and leads to persistent tissue damage. The short-lived prosurvival Bcl-2 family protein, Mcl-1 (myeloid cell leukemia-1), is instrumental in controlling apoptosis and consequently neutrophil lifespan in response to rapidly changing environmental cues during inflammation. This paper will focus on multiple levels of control of Mcl-1 expression and function and will discuss targeting Mcl-1 as a potential therapeutic strategy to enhance the resolution of inflammation through accelerating neutrophil apoptosis.

Indexed as

ApoptosisCell SurvivalHumansMyeloid Cell Leukemia Sequence 1 ProteinNeutrophilsProto-Oncogene Proteins c-bcl-2Myeloid Cell Leukemia Sequence 1 ProteinProto-Oncogene Proteins c-bcl-2apoptosiscaspasecyclin-dependent kinase inhibitorsformyl peptide receptorsgene transcriptioninflammationlipoxinsMcl-1 (myeloid cell leukemia-1)mitochondriaMNDA (myeloid nuclear differentiation antigen)Neutrophilsphosphorylationproteasomal degradationresolution of inflammationsepsisβ2 integrin

Identifiers

PMID22125448
PMCPMC3217587

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.